Predictive value of primary tumor 18F-FDG PET/CT metabolic parameters for lymph node metastasis in treatment-naïve ALK-positive NSCLC

PURPOSE: F-FDG PET/CT and lymph node metastasis (LNM) in treatment-naïve anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), and to evaluate their utility in discriminating the cases with radiographically occult LNM (OLNM). METHODS: F-FDG PET/CT before the treatment between October 2021 and December 2024. Primary tumor metabolic parameters, including SUVmax, SUVpeak, metabolic tumor volume (MTV), and total lesion glycolysis (TLG), were measured. Logistic regression analyses were performed to identify LNM predictors. Receiver operating characteristic curve analysis evaluated predictive performance, with area under the curve (AUC) was calculated. The relation between OLNM status and metabolic parameters of primary tumor was analyzed using Kruskal-Wallis test. RESULTS: Among 157 patients (62 males and 95 females; mean age 56 ± 11 years), 71 patients (45.2%) had pathologically confirmed LNM. Patients with LNM exhibited evidently larger primary tumor size and higher SUVmax, SUVpeak, MTV, and TLG than those without LNM (all P < 0.001). Univariate analysis showed primary tumor size, SUVmax, SUVpeak, MTV, and TLG were remarkedly associated with LNM. Multivariate analysis identified primary tumor size (OR: 1.043, 95%CI: 1.004-1.084; P = 0.032) and SUVmax (OR: 1.322, 95%CI: 1.159-1.532; P < 0.001) as independent predictors. The AUCs for tumor size, SUVmax, and combined factors were 0.76, 0.77, and 0.81, respectively. In addition, false-negative (OLNM-positive) cases showed markedly larger tumor size (P = 0.003) and higher TLG (P = 0.011) than true-negative cases. CONCLUSION: F-FDG PET/CT before treatment, particularly when combined with primary tumor size, may help stratify LNM risk in treatment-naïve ALK-positive NSCLC patients. These parameters may help identify OLNM, potentially guiding personalized lymph node dissection strategies and optimizing treatment plans.

Authors

Institutions

Publication Details

Journal
Cancer Imaging
Published
2026-05-29
DOI
https://doi.org/10.1186/s40644-026-01058-0
Primary Topic
Lung Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Predictive value of primary tumor 18F-FDG PET/CT metabolic parameters for lymph node metastasis in treatment-naïve ALK-positive NSCLC

Tingting Qiao, Jie Gu, Jin Zhao, Yangchun Chen
Cancer Imaging
Lung Cancer Diagnosis and Treatment
article

Predictive value of primary tumor 18F-FDG PET/CT metabolic parameters for lymph node metastasis in treatment-naïve ALK-positive NSCLC

Tingting Qiao, Jie Gu, Jin Zhao, Yangchun Chen
article en

Abstract

PURPOSE: F-FDG PET/CT and lymph node metastasis (LNM) in treatment-naïve anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), and to evaluate their utility in discriminating the cases with radiographically occult LNM (OLNM). METHODS: F-FDG PET/CT before the treatment between October 2021 and December 2024. Primary tumor metabolic parameters, including SUVmax, SUVpeak, metabolic tumor volume (MTV), and total lesion glycolysis (TLG), were measured. Logistic regression analyses were performed to identify LNM predictors. Receiver operating characteristic curve analysis evaluated predictive performance, with area under the curve (AUC) was calculated. The relation between OLNM status and metabolic parameters of primary tumor was analyzed using Kruskal-Wallis test. RESULTS: Among 157 patients (62 males and 95 females; mean age 56 ± 11 years), 71 patients (45.2%) had pathologically confirmed LNM. Patients with LNM exhibited evidently larger primary tumor size and higher SUVmax, SUVpeak, MTV, and TLG than those without LNM (all P < 0.001). Univariate analysis showed primary tumor size, SUVmax, SUVpeak, MTV, and TLG were remarkedly associated with LNM. Multivariate analysis identified primary tumor size (OR: 1.043, 95%CI: 1.004-1.084; P = 0.032) and SUVmax (OR: 1.322, 95%CI: 1.159-1.532; P < 0.001) as independent predictors. The AUCs for tumor size, SUVmax, and combined factors were 0.76, 0.77, and 0.81, respectively. In addition, false-negative (OLNM-positive) cases showed markedly larger tumor size (P = 0.003) and higher TLG (P = 0.011) than true-negative cases. CONCLUSION: F-FDG PET/CT before treatment, particularly when combined with primary tumor size, may help stratify LNM risk in treatment-naïve ALK-positive NSCLC patients. These parameters may help identify OLNM, potentially guiding personalized lymph node dissection strategies and optimizing treatment plans.

Cancer Imaging
Tongji University (CN), Shanghai Pulmonary Hospital (CN)
Reduced inequalities
Openalex Percentile: Top 6%
Lung Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.